文献速递急性肾损伤慢性肾脏病

全基因组荟萃分析发现快速肾功能下降的显著变异

Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline.
PubMed 文献 · Kidney Int · 2020-10-31

本研究对42项全基因组关联研究进行荟萃分析,采用两种eGFR快速下降定义(Rapid3和CKDi25),在6个位点发现7个独立变异,其中5个达全基因组显著性。高遗传风险个体(8-14个风险等位基因)相比低风险者(0-5个)急性肾损伤风险增加1.20倍(95%CI 1.08-1.33)。

要点

  • 鉴定出6个位点7个独立变异与eGFR快速下降相关,其中5个达全基因组显著性。
  • 高遗传风险(8-14个风险等位基因)与急性肾损伤风险增加1.20倍相关。
  • 这些位点为快速肾功能下降的机制研究和治疗靶点优先排序提供依据。

核心结论

  • 发现6个位点7个独立变异与eGFR快速下降相关,其中5个达全基因组显著性。
  • 高遗传风险个体急性肾损伤风险增加1.20倍(95%CI 1.08-1.33)。

研究设计与样本

  • 对慢性肾脏病遗传学联盟和英国生物银行42项全基因组关联研究进行荟萃分析。
  • Rapid3定义:eGFRcrea年下降≥3 mL/min/1.73m2,含34,874例病例和107,090例对照。
  • CKDi25定义:随访时eGFRcrea下降≥25%且<60 mL/min/1.73m2(基线≥60),含19,901例病例和175,244例对照。

主要发现

  • Rapid3和/或CKDi25共发现7个独立变异,分布于6个位点。
  • 5个变异位于4个位点达全基因组显著性:UMOD-PDILT(2个)、PRKAG2、WDR72、OR2S2。
  • 2个变异位于265个已知eGFRcrea变异中:GATM和LARP4B附近。
  • OR2S2位点为任何eGFRcrea性状的新位点。
  • 5个全基因组显著变异对血尿素氮年变化或胱抑素C基于的eGFR有支持效应,GATM和LARP4B无此效应。

关键数值与推荐

  • 高遗传风险组(8-14个风险等位基因)对比低风险组(0-5个),急性肾损伤风险比1.20(95%CI 1.08-1.33)。

临床怎么用

  • 遗传风险评分可能有助于识别快速肾功能下降和急性肾损伤高风险个体。
  • 鉴定出的位点可优先用于治疗靶点开发和机制研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rapid decline of glomerular filtration rate estimated from creatinine (eGFRcrea) is associated with severe clinical endpoints. In contrast to cross-sectionally assessed eGFRcrea, the genetic basis for rapid eGFRcrea decline is largely unknown. To help define this, we meta-analyzed 42 genome-wide association studies from the Chronic Kidney Diseases Genetics Consortium and United Kingdom Biobank to identify genetic loci for rapid eGFRcrea decline. Two definitions of eGFRcrea decline were used: 3 mL/min/1.73m2/year or more ("Rapid3"; encompassing 34,874 cases, 107,090 controls) and eGFRcrea decline 25% or more and eGFRcrea under 60 mL/min/1.73m2 at follow-up among those with eGFRcrea 60 mL/min/1.73m2 or more at baseline ("CKDi25"; encompassing 19,901 cases, 175,244 controls). Seven independent variants were identified across six loci for Rapid3 and/or CKDi25: consisting of five variants at four loci with genome-wide significance (near UMOD-PDILT (2), PRKAG2, WDR72, OR2S2) and two variants among 265 known eGFRcrea variants (near GATM, LARP4B). All these loci were novel for Rapid3 and/or CKDi25 and our bioinformatic follow-up prioritized variants and genes underneath these loci. The OR2S2 locus is novel for any eGFRcrea trait including interesting candidates. For the five genome-wide significant lead variants, we found supporting effects for annual change in blood urea nitrogen or cystatin-based eGFR, but not for GATM or LARP4B. Individuals at high compared to those at low genetic risk (8-14 vs. 0-5 adverse alleles) had a 1.20-fold increased risk of acute kidney injury (95% confidence interval 1.08-1.33). Thus, our identified loci for rapid kidney function decline may help prioritize therapeutic targets and identify mechanisms and individuals at risk for sustained deterioration of kidney function.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Gorski M, Jung B, Li Y, et al. Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. Kidney Int. 2020. PMID: 33137338. doi:10.1016/j.kint.2020.09.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。